Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Jun 15, 2020- FreeStyle Libre 2 is the only integrated continuous glucose monitoring (iCGM) system available that continuously transmits glucose data every minute with customizable, optional real-time alarms to alert users when their glucose is high or low without scanning- Now for children (ages 4 and older) and adults with diabetes, this latest technology is the first and only iCGM that sustains performance for up to 14 days, providing trends, insights and actionable data- FreeStyle Libre 2 system includes a self-applied sensor (the size of two-stacked quarters) that is easiest glucose sensor to apply[1] and worn on the back of the upper arm, eliminating the need for painful fingersticks to test glucose levels[2]- FreeStyle Libre portfolio has been extensively studied with the most real-world users, delivering proven health outcomes[3]- FreeStyle Libre 2 system offers enhanced features at the same affordable price as FreeStyle Libre 14 day system, which is a third of the cost of other CGMs[4]
Jun 13, 2020- Real-world data(1) presented at the American Diabetes Association 80th Scientific Sessions suggest people with type 2 diabetes can achieve similar outcomes to adding insulin therapy for both long-acting insulin or non-insulin users- A separate late-breaking trial(2) demonstrates FreeStyle Libre portfolio use is associated with significant reductions of acute diabetes events and hospitalizations for a similar population- May 21, 2020- Urgent care clinic study shows ID NOW test performance of ≥94.7% positive agreement (sensitivity) and ≥98.6% negative agreement (specificity) compared to lab-based PCR reference tests- The Everett Clinic study shows 91.3% positive agreement and 100% negative agreement- Ongoing study of hospitalized and nursing home patients tested with late symptom onset shows ≥83.3% positive agreement and ≥96.5% negative agreement- Abbott's studies suggest ID NOW performs best in patients tested earlier post symptom onset- ID NOW delivers results in minutes rather than days and is helping reduce the spread of infection by detecting more positive patients faster than would otherwise be the case
- May 21, 2020- Abbott's antibody test to be deployed as part of the UK Secretary of State for Health's initiative for highly-reliable, large-scale antibody testing- European-made blood test will run on Abbott's ARCHITECT® i1000SR and i2000SR, as well as its Alinity™ i laboratory instruments- 800,000 Abbott tests have already been delivered to NHS laboratories across the UK- Test demonstrated reliable results with 99.6% specificity and 100% sensitivity for patients tested 14 days or more after symptoms started